A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma

Maria Brambati, Chiara Giuffrè, Alessandro Marchese, Francesco Bandello, Giulio Maria Modorati, Elisabetta Miserocchi

Research output: Contribution to journalArticlepeer-review

Abstract

We report a case of ocular drug toxicity consistent with bilateral Vogt-Koyanagi-Harada (VKH) like disease in a patient with cutaneous melanoma treated with Dabrafenib/Trametinib therapy. A 53-year-old man with a history of metastatic cutaneous melanoma, treated with Dabrafenib/Trametinib, developed a severe acute panuveitis with granulomatous anterior uveitis and multiple serous retinal detachments. The ocular inflammatory reaction was classified as a bilateral Vogt-Koyanagi-Harada disease. Intraocular inflammation resolved after discontinuation of chemotherapeutic agents and aggressive topical and systemic corticosteroid therapy. The present case outlines the importance of recognizing VKH-like syndrome as a possible consequence of therapy with dabrafenib and trametinib.

Original languageEnglish
Pages (from-to)NP109-NP113
JournalEuropean Journal of Ophthalmology
Volume32
Issue number1
DOIs
Publication statusPublished - Jan 2022

Keywords

  • choroidal/retinal inflammation
  • Immunology
  • panuveitis
  • pharmacology
  • RETINA
  • systemic drug retinal toxicity
  • UVEA
  • UVEITIS

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma'. Together they form a unique fingerprint.

Cite this